Search
V591
go.drugbank.com/drugs/DB16438InvestigationalThrough Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593]. … The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery[L30593].
Evogliptin
go.drugbank.com/drugs/DB12625InvestigationalEvogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.
Categories: Drugs Used in Diabetes, DPP-IV InhibitorsOlorofim
go.drugbank.com/drugs/DB15245InvestigationalOlorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).
Fosravuconazole
go.drugbank.com/drugs/DB15204InvestigationalFosravuconazole is under investigation in clinical trial NCT03378661 (BENDITA BEnznidazole New Doses Improved Treatment and Associations).
Categories: Antifungals for Systemic Use, Antifungals for Dermatological UseD-fluoromethyltyrosine F-18
go.drugbank.com/drugs/DB15296InvestigationalD-fluoromethyltyrosine F-18 is under investigation in clinical trial NCT01089998 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety … , Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations).
Chlorocresol
go.drugbank.com/drugs/DB16864InvestigationalCategories: Compounds used in a research, industrial, or household settingHydrogen
go.drugbank.com/drugs/DB15127InvestigationalHydrogen is under investigation in clinical trial NCT02830854 (Molecular Hydrogen for Cognitive Function and Performance in Elderly).
Fluasterone
go.drugbank.com/drugs/DB06250ExperimentalHas antiproliferative effects on HIV-1 and reduces HIV-1 replication.
Halofuginone
go.drugbank.com/drugs/DB04866InvestigationalVet approvedCollgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000. … Halofuginone also effectively suppresses tumor progression and metastasis in mice.